Profit and cash flow diverged
Reported profit rose 9.6% but operating cash flow fell 68.8% — worth investigating whether the profit is being collected.
Importance 69 / 95 · cash quality
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Reported profit rose 9.6% but operating cash flow fell 68.8% — worth investigating whether the profit is being collected.
Importance 69 / 95 · cash quality
Revenue grew 16.8% but profit grew 9.6%, so the company kept less of each rupee of revenue as profit.
Importance 63 / 95 · growth
Revenue grew 16.8% but only 0.41× of reported profit came through as operating cash.
Importance 62 / 95 · cash quality
ROE of 18.3% beats the pharmaceuticals median (14.4%) while P/B (4.06×) sits below it (4.74×).
Importance 62 / 95 · valuation
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 9.5% a year over 4 years, from ₹7,982 cr in FY2022 to ₹11,484 cr in FY2026. Net profit grew 42.7% a year over the same period.
Revenue grew 16.8% but profit grew 9.6%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Revenue compounded at 15.5% a year over 4 years (₹15,265 → ₹27,148).
Revenue grew 16.8% year on year (FY2025 → FY2026).
In Q2 FY27 (Jul–Sep 2026), revenue was ₹7,910 cr (up 29.2% on the same quarter last year) and net profit ₹928 cr (down 25.1%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 revenue was ₹7,910 cr, up 29.2% from ₹6,123 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 net profit declined 25.1% while revenue grew 29.2% vs the same quarter last year — a gap of 54.3 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
Q2 FY27 net profit was ₹928 cr, down 25.1% from ₹1,239 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 5,269 | +17.0% | 1,026 | +29.9% | 19.5% |
| Q4 FY25 | 6,528 | +18.0% | 1,244 | −0.2% | 19.1% |
| Q1 FY26 | 6,574 | +5.9% | 1,521 | +2.6% | 23.1% |
| Q2 FY26 | 6,123 | +16.9% | 1,239 | +34.6% | 20.2% |
| Q3 FY26 | 6,865 | +30.3% | 1,023 | −0.3% | 14.9% |
| Q4 FY26 | 7,587 | +16.2% | 1,341 | +7.8% | 17.7% |
| Q1 FY27 | 8,017 | +22.0% | 990 | −34.9% | 12.4% |
| Q2 FY27 | 7,910 | +29.2% | 928 | −25.1% | 11.7% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 48.7% in FY2026, against 26.3% in FY2022. ROE was 15.9% and ROCE 16.6% in FY2026.
EBITDA margin of 33.1% is the widest in 4 years (prior range 23.4% to 31.5%).
Rule MARGIN_AT_MULTI_YEAR_HIGH
ROE of 18.3% is well above the pharmaceuticals median of 14.4%.
EBITDA margin improved from 31.5% to 33.1% of revenue.
Debt-to-equity was 0.31x in FY2026, against 0.20x in FY2022; interest coverage 10.42x. Operating cash flow was 0.63x net profit.
Reported profit rose 9.6% but operating cash flow fell 68.8% — worth investigating whether the profit is being collected.
Rule PROFIT_UP_CASH_DOWN
Revenue grew 16.8% but only 0.41× of reported profit came through as operating cash.
Debt-to-equity of 0.40× is the highest in 4 years (prior range 0.03× to 0.22×).
Operating cash flow was only 0.41× reported profit (FY2026).
Free cash flow has been positive in 4 of the last 5 years.
Debt-to-equity rose from 0.12× to 0.40× year on year.
Within its 12-company Pharmaceuticals peer group, it ranks 2 of 12 on return on equity and 3 of 12 on EBITDA margin. Its P/E of 28.1 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
ZYDUSLIFE · 6th of 12 · set median 14.8%
ZYDUSLIFE · 3rd of 12 · set median 28.7%
ZYDUSLIFE · 2nd of 12 · set median 14.4%
ZYDUSLIFE · 3rd of 12 · set median 45.3×
ROE of 18.3% beats the pharmaceuticals median (14.4%) while P/B (4.06×) sits below it (4.74×).
Rule STRONG_RETURNS_AT_DISCOUNT
On the trailing twelve months. Last full year: P/E 23.5× · P/S 4.3× · ROE 18.3%. TTM and full-year profit differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 28.8% over 1 year and up 87.0% over 3 years (23.2% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 3.9% below its 52-week high; price history covers less than 5 years.
Over 4 years the stock returned 23.2% a year while profit compounded at 2.6% a year.
Rule STOCK_RAN_AHEAD
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 7,982 | 8,732 | 10,819 | 15,116 | 11,484 |
| Total income | 8,161 | 9,280 | 11,904 | 15,813 | 13,152 |
| EBITDA | 2,097 | 3,003 | 5,144 | 8,433 | 5,593 |
| Profit before tax | 1,164 | 2,032 | 4,240 | 7,445 | 4,382 |
| Net profit | 858 | 1,529 | 3,442 | 5,775 | 3,560 |
| EPS (₹) | 8.4 | 15.1 | 34.0 | 57.4 | 35.4 |
| Net worth | 13,241 | 13,639 | 15,717 | 21,190 | 23,672 |
| Total debt | 2,663 | 4,823 | 6,174 | 8,339 | 7,431 |
| Operating cash flow | 1,311 | 1,078 | 1,999 | 3,114 | 2,234 |
| Free cash flow | 769 | 420 | 1,434 | 2,257 | 1,351 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 9.4 | 23.9 | 39.7 | -24.0 |
| Profit growth YoY | — | 78.2 | 125.1 | 67.8 | -38.4 |
| Profitability | |||||
| EBITDA margin % | 26.3 | 34.4 | 47.5 | 55.8 | 48.7 |
| Net margin % | 10.5 | 16.5 | 28.9 | 36.5 | 27.1 |
| Return on equity % | 6.5 | 11.4 | 23.4 | 31.3 | 15.9 |
| Return on capital % | 10.2 | 14.6 | 23.0 | 30.8 | 16.6 |
| Leverage & cash | |||||
| Debt to equity | 0.20 | 0.35 | 0.39 | 0.39 | 0.31 |
| Cash flow ÷ profit | 1.53 | 0.71 | 0.58 | 0.54 | 0.63 |
| Current ratio | 1.70 | 2.57 | 3.11 | 1.95 | 2.91 |